cyrilzakka/clinical-trials huggingface dataset:
Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammography and before breast biopsy if biopsy is needed. The final diagnostic workup outcome of these enrolled patients needs to include at least 30 confirmed cancers cases.


Eligibility Criteria:
Inclusion Criteria:

* Female sex
* Age 35 years or older
* Any ethnicity
* Have an abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality.
* Will undergo study imaging within four weeks from the date of diagnostic mammography, prior to breast biopsy (if needed).
* Able to provide informed consent
* Post-menopausal, surgically sterile, or effective birth control. For women of childbearing potential, negative pregnancy test or has signed pregnancy test waiver
* If required by standard of care, eGFR \>45 within 48 hours to 6 weeks of CE-CBBCT exam

Exclusion Criteria:

* Pregnancy
* Lactation
* Unknown pregnancy status AND
* has refused pregnancy testing and
* has refused to sign a pregnancy test waiver
* Women who are unable or unwilling to understand or to provide informed consent
* Women with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
* Women who are unable to tolerate study constraints.
* Women who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to):

  * Treatment for enlarged thymus gland as an infant
  * Irradiation for benign breast conditions, including breast inflammation after giving birth
  * Treatment for Hodgkin's disease
  * Women who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  * Women who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to):
* Tuberculosis
* Severe scoliosis

Additional Exclusion Criteria Due To Contrast Injection:

* Allergic to iodinated contrast material
* Previous non-ionic contrast reaction
* Any conditions below regardless of eGFR

  * Renal Disease
  * Chronic renal dysfunction
  * Renal Transplant (or waiting for a transplant)
  * One kidney or other birth defect
  * Polycystic Kidneys
  * Renal Tumor/Renal Cancer
  * History of liver failure/cirrhosis/liver transplant/pending liver transplant
  * Congestive heart failure
  * Multiple myeloma
  * Hyperthyroidism
  * Pheochromocytoma
  * Sickle Cell Disease
  * Asthma requiring daily use of inhaler Additional exclusion criteria due to machine limitations
* Patient's body weight is over the limit of the scanner table (440 lbs or 200kg)
Distribution of Bacteria in OME After Radiotherapy For NPC.

To observe the prognostic difference of tympanocentesis in different kinds of otitis media effusion.

This study is a prospective, observational clinical study to observe the difference in prognosis of tympanocentesis in different kinds of otitis media effusion (OME), especially OME after radiotherapy for nasopharyngeal carcinoma (NPC). A total of 234 patients diagnosed with OME who are given the treatment of tympanocentesis only, including outpatient and inpatient patients, were included in the study. The middle ear effusion collected during the tympanocentesis is sent for bacterial culture. The positive rate of the effusion and the recurrence rate within 24 weeks will be compared in order to figure out whether bacterial infection is an important influencing factor for some kinds of OME in addition to eustachian tube dysfunction, which is acknowledged.

Eligibility Criteria:
Inclusion Criteria:

* patients clinical diagnosis of OME or OME after radiotherapy for NPC (Diagnostic criteria: fluid visible in the middle ear and a type B tympanogram).
* patients volunteered to participate in the study and signed the informed consent

Exclusion Criteria:

* NPC recurrence or other malignant tumor after radiotherapy.
* clear diagnosis of Eustachian ostium atresia or nasal obstruction diseases, such as severe deviated nasal septum, choanal atresia, osteoradionecrosis of skull base after radiotherapy, etc.
* pregnant and lactating women.
* patients with severe underlying diseases or with severe liver and kidney dysfunction.
* patients who could not cooperate (including poor hearing and radiation encephalopathy)
* patients with other middle ear diseases, such as middle ear cholesteatoma, osteoradionecrosis of temporal bone after radiotherapy, etc.
* severe deglutition disorders
* cleft palate
Immediate Simultaneous Bilateral Cataract Surgery

To evaluate the safety and efficacy of treating visually significant bilateral cataract with the newer technique of Immediate Simultaneous Bilateral Cataract Surgery (ISBCS) versus the conventional technique of Delayed Sequential Bilateral Cataract Surgery (DSBCS) in a select patient population.


Eligibility Criteria:
Inclusion Criteria:

* Age 30-100
* Candidate for topical anesthesia
* Signed the informed consents

Exclusion Criteria:

* Allergies to medications used in study
* Cannot have topical anesthesia
* Unwilling to participate in research trial
* Have any other significant ocular comorbidities
* Have known systemic immuno-compromised state
Telehealth Group Counseling and Preventive Care for Women

The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic cardiovascular disease (ASCVD).

This will be an electronic survey study of female patients with known atherosclerotic cardiovascular disease (ASCVD) who are managed by providers in the Weill Cornell Medicine Cardiology Division and self-select into this telehealth group education series. Group health counseling will be administered via the Weill Cornell Medicine approved telehealth platform at the time of participation. Participants will have the option to choose the session topic of their choice and will have the opportunity to participate in 1-5 sessions over 12 weeks, depending on their preference. Each session will occur regardless of number of participants but will be capped at 12 participants, anticipating that two will not join. Once consent is obtained, baseline characteristics of participants will be collected via chart review. Demographics such as age, race, insurance carrier, and clinician-documented diagnoses, such as ASCVD, hypertension (HTN), hyperlipidemia (HLD), and diabetes mellitus (DM), will be collected. Prior to each group health counseling session, an initial survey will be provided to patients who are chosen for and consent to this study. This survey will ask patients about their demographics, self-reported diagnoses, current level of satisfaction about their understanding of their diagnoses, reasons for participating in the study, and history of previous participation in telehealth group counseling. After the sessions, a post-session survey will be provided to all participants and will assess patient understanding, including diagnoses and medications, satisfaction with the format, satisfaction with the provider, how many sessions were attended, reasons for attending more than one session, and recommendation of this format to others. All data will be de-identified prior to analysis and will remain confidential among investigators.

Eligibility Criteria:
Inclusion criteria:

* Female patients
* Age 18 and older
* Patients who are managed by providers at the Weill Cornell Medicine Women's Heart Program
* Women with evidence of atherosclerotic cardiovascular disease (ASCVD) and diagnoses of chest pain, myocardial infarction/heart attack (myocardial infarction - non ST elevation NSTEMI, ST elevation STEMI), coronary artery disease, acute coronary syndrome, unstable angina, atherosclerotic cardiovascular disease, hypertension (HTN), hyperlipidemia (HLD), diabetes (DM), and/or palpitations (as confirmed by clinician referral to study and chart review)

Exclusion criteria:

• Women with risk factors (ex: HTN, HLD, DM) but no evidence of ASCVD
Changes of Higher-Order Aberrations After Different Types of LASIK in Myopia

This prospective comparative interventional study will enroll patients with low and moderate myopia who seek laser vision correction at Sohag Center for LASIK and Corneal Surgeries, Sohag, Egypt. Eyes included will be divided into 3 groups according to the type of refractive surgery used (conventional LASIK, Femto-LASIK and PRK) and each group will be subdivided into 2 groups according to the degree of myopia (low and moderate).


Eligibility Criteria:
Inclusion Criteria:

Age: 18 - 45 years old.

Refraction:

Low and moderate grades of myopia will be included:

(According to manifest refraction) low (\[0\] - ≤ \[-3\] diopters) Moderate (\[-3\] - ≤ \[-6\] diopters) With cylinder ≤ \[-1.5\] diopters.

Exclusion Criteria:

Any ocular surgery or medication, corneal opacities, pregnancy, lactation and keratoconus.
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)

Alzheimer's disease (AD), is associated with behavioral disturbances in approximately 50% of AD patients in Beijing. Agitation, and aggression specifically, is considered the most serious noncognitive symptom experienced in patients with dementia. Memantine is a recognized treatment for Alzheimer's disease either alone or in combination with cholinesterase inhibitors. Its efficacy in vascular dementia is also established. Family members continue to play a central role in home care for the demented elderly in China. This proposal is to conduct a study in Beijing, China to investigate the efficacy and safety of Memantine in the treatment of agitation and aggression in AD patients. In addition, this proposal aims to explore the impact of memantine on caregiver burden of AD patients in Chinese culture.


Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent
2. Clinical diagnosis of Alzheimer's disease.
3. Having at least a minimum aggression score on the Cohen-Mansfield Agitation Inventory (CMAI): a score of ≥ 4 on at least 1 aggressive item, or a score of 3 on at least 2 aggressive items, or a score of 2 on at least 3 aggressive items, or 2 aggressive items occurring at a frequency of 2 and 1 at a frequency of 3.
4. Availability of a responsible family member or carer to ensure treatment compliance and provide information for informant assessments.

Exclusion Criteria:

1. Unavailability of a responsible family member or carer
2. Severe renal impairment.
3. History of seizures
4. Diagnosis of any concomitant life threatening illness.
Effectiveness of a Cancer Center Based Physical Activity Intervention

Purpose: Examine the effectiveness of cancer center-based physical activity counseling on physical activity rates and quality of life in breast cancer survivors.

Hypothesis: Participants in the intervention group will indicate greater step counts and quality of life at the end of the intervention compared to the control group


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of breast cancer within the last 5 years
* Over the age of 18 years
* female

Exclusion Criteria:

* Non-ambulatory
* Poor cognitive function
* Contraindications for exercise as determined by the PAR-Q
Anesthesia for Obese Patients: Desflurane Versus Xenon

Obesity is increasing in France, resulting in an increased demand for bariatric surgery. However obesity also alters physiopathological pathways and the pharmacokinetics of anesthestic agents. The investigators objective is to compare, among morbidly obese patients, the immediate and intermediary emergence kinetics after balanced anesthesia using remifentanil associated either with desflurane (reference arm) or with xenon (experimental arm).


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) I to III
* requires bariatric surgery
* body mass index (BMI) \>= 35 kg/m2
* patient speaks and writes French
* patient has signed consent form
* patient enrolled in a social security program

Exclusion Criteria:

* patient refuses to sign consent
* ASA IV or more
* patient is pregnant or breastfeeding
* history of hyperthermy (or suspicion, or family history thereof)
* history of liver disease, icterus, unexplained fever, or eosinophilia after administration of a halogen anesthesia
* patient has symptomatic gastro-oesophagean reflux
* patient has hypersensitivity to one or more of the following substances: propofol, remifentanil, celocurine, cisatracurium, rocuronium, desflurane, xenon, paracetamol, ketoprofen, nefopam, tramadol
* patient has obstructive respiratory failure (chronic obstruction pneumopathy, asthma) or has heart disease with severly altered cardiac function
* patient has high intracranial pressure
* patient requires high concentrations of oxygen (fio2\>40%)
* patient has a neuro-sensorial deficient which prevents reading, writing, or response to simple oral commands (severe deafness, language impairment...)in the absence of a prothesis
* patient has a psychiatric pathology, or chronically consumes alcohol or other mind-altering substance
* patient has had general anesthesia in the last 15 days
* patient under guardianship
* impossible to correctly communicate information to the patient
* absence of efficient contraception for women of childbearing age
* participation in another study within the last 3 months
A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents

The aim of the following pilot study is to examine boredom in a community sample of adolescents and a clinical sample of adolescents. This is important in order to examine differences among healthy adolescents and adolescents with mental illness.

Boredom has been recognized as a significant problem in a wide variety of areas. However, limited research has been focused on this construct (Vodanovich \& Watt, 1999). Research into boredom in adolescents is especially lacking in the psychological literature. This is surprising given that adolescence is a time marked by change, stress, and identity issues.

The aim of the following pilot study is to examine boredom in a community sample of adolescents and a clinical sample of adolescents. This is important in order to examine differences among healthy adolescents and adolescents with mental illness, such as depression, anxiety, and ADHD. This has implications for both prevention and intervention strategies and programs, such as the assessment and treatment of adolescents with mental illness. Hence, the results of this study will be important in providing an evidence-based practice in the treatment of mental illness in adolescents.

Participants will be asked to complete one survey, the Boredom Proneness Scale (Farmer \& Sundberg, 1986), and a demographic background form to measure gender, date of birth, country of birth, etc. The community sample of adolescents will be recruited from secondary schools in Victoria. The clinical sample of adolescents will be recruited from the Alfred Child and Adolescent Mental Health Service. It is envisaged that about 100 adolescents from each sample will be recruited to participate.

Eligibility Criteria:
Inclusion Criteria:

* 13-18 years of age
* has consenting guardian

Exclusion Criteria:

* unable to sufficiently understand self report measure
* IQ \< 70
Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed cases of hematological malignancis.

Exclusion Criteria:

* Known cases of hematological malignancies and on treatment.
Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects aged above 20
* Patient with overactive bladder symptoms lasting at least 6 months

Exclusion Criteria:

* Patient with a history of surgery or a disease that may affect bladder function.
Effect of Open Kinetic Chain Shoulder Exercises on Scapulothoracic Muscle Activity on Stable and Unstable Ground

Exercises used in shoulder rehabilitation compose of open kinetic chain and closed kinetic chain exercises.The force formed on the trunk and legs is transferred to the shoulder in open and closed kinetic chain exercises before shoulder muscles activation. It was shown that trunk and leg muscle activity changes when they are performed in different ground. But it is unknown how this alteration effect shoulder muscle activity. This will be provide a significance approach due to incremented of shoulder muscle activity is important for shoulder rehabilitation setting. To achieve this aim that is rising of muscle activity, various approach is applied including alteration of ground which individual performed exercise on it. And, it was shown that closed cinetic chain exercise which performed on different ground change shoulder muscle activity. However, it is unknown whether alteration of ground effect shoulder muscle activity or not in open cinetic chain exercise. That's why the aim of this study is to investigate alteration of scapulothoracic shoulder muscle activity in open cinetic chain shoulder exercise which enforced different ground.


Eligibility Criteria:
Inclusion Criteria:

* Being healthy
* Right hand dominant
* Ages between 20-45 years
* To be volunteer participate in the study

Exclusion Criteria:

* Having any shoulder pain in current or in the past
* Any previous surgery
* Pain in any part of the body
* Doing regularly a professional sports
* Neurological disease
* Systemic disease
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.


Eligibility Criteria:
Abbreviated Inclusion Criteria:

1. Age 18 years or older, is willing and able to provide informed consent
2. Histologically or cytologically confirmed diagnosis of metastatic PDAC.
3. No prior systemic treatment for metastatic disease.
4. Evidence of measurable disease per RECIST 1.1.
5. Appropriate for treatment with nab-paclitaxel and gemcitabine chemotherapy.
6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

Abbreviated Exclusion Criteria:

1. History of clinically significant allergy or hypersensitivity to planned study treatment components or to any monoclonal antibody
2. Use of investigational agent within 14 days prior to the first dose of study drug
3. History of autoimmune disease
4. Subject has received live vaccine within 28 days prior to the first dose of study drug
5. Has uncontrolled intercurrent illness
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain reaction, Western blotting method was used to determine the expression level of fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver fibrosis.

Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of tauroursodeoxycholic acid has been very active, and its chemical synthesis has also attracted much attention. The usage is swallowing with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver biopsy was performed after 6 months. Telling the patient to swallow with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver B-ultrasound biopsy was performed to observe the effect.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of liver cirrhosis and liver fibrosis in patients requiring medical treatment.

Exclusion Criteria:

* Patients with end-stage cirrhosis, liver failure, etc. who need liver transplantation.
Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury

A traumatic brain injury (TBI) is among the most frequent reasons for neurological impairment in young people. The investigators investigated whether vitamin B12 vs B3 therapy could reduce the severity of traumatic brain injury (TBI) due to their positive effects on axon regrowth following nerve damage. The method utilized was a series of non-random samples. With a 95% confidence interval and a 5% margin of error, a total sample of 300 patients was estimated using Epi Info. Participants in our study comprised both boys and girls with severe TBI ages 6 to 15 years old.

Two groups of 300 children were recruited. B3 (16 mg/day) was administered to group 1 and B12 (125-250 mcg/day) was provided to group 2. It is evaluated through follow-ups on a range of tests to evaluate cognitive capacity, sensorimotor activity and staircase test (working and reference memory). Pre-and post-treatment GCS measurements were conducted. Three weeks and a year following the treatment of TBI, children underwent neurobehavioral testing. The measurement of gait analysis was done. The standard error and mean of statistically examined data were shown by paired t-test.

A traumatic brain injury (TBI) is among the most frequent reasons for neurological impairment in young people. The investigators investigated whether vitamin B12 vs B3 therapy could reduce the severity of traumatic brain injury (TBI) due to their positive effects on axon regrowth following nerve damage. The method utilized was a series of non-random samples. With a 95% confidence interval and a 5% margin of error, a total sample of 300 patients was estimated using Epi Info. Participants in our study comprised both boys and girls with severe TBI ages 6 to 15 years old.

Two groups of 300 children were recruited. B3 (16 mg/day) was administered to group 1 and B12 (125-250 mcg/day) was provided to group 2. It is evaluated through follow-ups on a range of tests to evaluate cognitive capacity, sensorimotor activity and staircase test (working and reference memory). Pre-and post-treatment GCS measurements were conducted. Three weeks and a year following the treatment of TBI, children underwent neurobehavioral testing. The measurement of gait analysis was done. The standard error and mean of statistically examined data were shown by paired t-test.

Eligibility Criteria:
Inclusion Criteria:

* Children aged 6 to 15 years old
* Children with severe TBI of
* Children of both genders

Exclusion Criteria:

* Those with mild injury
* Stable Glasgow Coma Scale
* Not willing to consent